Evgenia I. Zhelnova
Research Subjects
Evgenia I. Zhelnova has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Elena N. Misyurina
Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
22 shared publications - Elena A. Baryakh
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
21 shared publications - Konstantin V. Yatskov
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
19 shared publications - Olga L. Kochneva
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
18 shared publications - Tatyana Nikolaevna Tolstykh
Moscow City Clinical Hospital No. 52, Moscow Healthcare Department
17 shared publications - Tatyana S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department. Moscow, Russian Federation;I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University). Moscow, Russian Federation; Moscow Clinical Science and Research Center 52,Moscow,Russia; Department of Hematology,Sechenov University,Moscow,Russia; Vavilov Institute of General Genetics,Moscow,Russia, Russia
17 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 41-50
Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 41-50
Open AccessMultiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.
- Open Access
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 242-249
Myeloid Sarcoma with Skin and Spinal Lesions and KRAS Gene Mutation, Complicated by Secondary Hemophagocytic Syndrome: A Case Report and Literature Review
Myeloid sarcoma (MS) is a rare hematologic tumor of immature myeloid cells with lesions located outside the bone marrow. The disease can develop de novo as extramedullary myeloid tumor, be a manifestation of acute myeloid leukemia (AML) or be diagnosed as an AML relapse after previously achieved remission. MS occurs in all age groups, although more commonly in elderly people. Diagnosis is based on immunomorphological and molecular genetic analyses of the tumor tissue. The most effective treatment regimens in MS are those used for AML therapy with subsequent allogeneic hematopoietic stem cell transplantation provided that the first complete remission was achieved. In addition to that, radiotherapy as well as biological and targeted drugs are administered. Nevertheless, the prognosis of the disease remains generally unfavorable. The present paper reports a clinical case of MS with KRAS mutation, tumor skin and Th5–Th6 lesions, spinal cord compression, and developing flaccid paraplegia. The patient received chemotherapies of varying intensity as well as hypomethylating agents combined with venetoclax and the targeted drug trametinib. The course of the disease was complicated by secondary hemophagocytic syndrome (SHS). The present case report demonstrates the challenges of both diagnosis and treatment of this rare and poor-prognosis extramedullary myeloid tumor complicated by SHS.
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 242-249
Open AccessMyeloid Sarcoma with Skin and Spinal Lesions and KRAS Gene Mutation, Complicated by Secondary Hemophagocytic Syndrome: A Case Report and Literature Review
Myeloid sarcoma (MS) is a rare hematologic tumor of immature myeloid cells with lesions located outside the bone marrow. The disease can develop de novo as extramedullary myeloid tumor, be a manifestation of acute myeloid leukemia (AML) or be diagnosed as an AML relapse after previously achieved remission. MS occurs in all age groups, although more commonly in elderly people. Diagnosis is based on immunomorphological and molecular genetic analyses of the tumor tissue. The most effective treatment regimens in MS are those used for AML therapy with subsequent allogeneic hematopoietic stem cell transplantation provided that the first complete remission was achieved. In addition to that, radiotherapy as well as biological and targeted drugs are administered. Nevertheless, the prognosis of the disease remains generally unfavorable. The present paper reports a clinical case of MS with KRAS mutation, tumor skin and Th5–Th6 lesions, spinal cord compression, and developing flaccid paraplegia. The patient received chemotherapies of varying intensity as well as hypomethylating agents combined with venetoclax and the targeted drug trametinib. The course of the disease was complicated by secondary hemophagocytic syndrome (SHS). The present case report demonstrates the challenges of both diagnosis and treatment of this rare and poor-prognosis extramedullary myeloid tumor complicated by SHS.
- Open Access
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 171-176
Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % of standard induction therapy recipients. The survival of program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) is usually planned and performed in young MM patients. However, the program HD patients are often excluded from the high-dose chemotherapy protocols with subsequent auto-HSCT due to the therapy associated toxicity risk. AIM. To assess the efficacy and safety of auto-HSCT in MM complicated by dialysis-dependent renal failure. MATERIALS & METHODS. In the period from 2015 to 2022, 14 program HD patients (8 men and 6 women) received auto-HSCT at the City Clinical Hospital No. 52. The median age was 53 years (range 43–66 years). In two patients, tandem transplantation was performed. Melphalan 140 mg/m2 (n = 10) was administered for pre-transplant conditioning. In 4 patients, bendamustine 200 mg/m2 was added to melphalan in the conditioning regimen. The median transfused СD34+ cell count was 3.61 × 106/kg (range 1.34–9.69 × 106/kg). By the time of completing bortezomib and/or lenalidomide induction therapy, complete remission (CR) was achieved in 5 patients, other 5 patients showed very good partial remission (VGPR), and in 4 patients partial remission (PR) was registered. RESULTS. As reported by the control follow-up on Day +100 after auto-HSCT, all patients demonstrated further deepening of antitumor response. By this time, CR in 11 (79 %) patients and VGPR in 2 (14 %) patients were registered, whereas 1 (7 %) patient maintained PR. Renal response and HD independence were achieved in 8 (57 %) out of 14 patients enrolled in the trial. In the total group (n = 14), the 3-year event-free survival was 50 % and overall survival was 78 %. CONCLUSION. Dialysis-dependent renal failure in MM patients is no contraindication to auto-HSCT. The latter will improve chemotherapy outcomes and make it possible to achieve renal response and HD independence.
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 171-176
Open AccessAutologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % of standard induction therapy recipients. The survival of program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) is usually planned and performed in young MM patients. However, the program HD patients are often excluded from the high-dose chemotherapy protocols with subsequent auto-HSCT due to the therapy associated toxicity risk. AIM. To assess the efficacy and safety of auto-HSCT in MM complicated by dialysis-dependent renal failure. MATERIALS & METHODS. In the period from 2015 to 2022, 14 program HD patients (8 men and 6 women) received auto-HSCT at the City Clinical Hospital No. 52. The median age was 53 years (range 43–66 years). In two patients, tandem transplantation was performed. Melphalan 140 mg/m2 (n = 10) was administered for pre-transplant conditioning. In 4 patients, bendamustine 200 mg/m2 was added to melphalan in the conditioning regimen. The median transfused СD34+ cell count was 3.61 × 106/kg (range 1.34–9.69 × 106/kg). By the time of completing bortezomib and/or lenalidomide induction therapy, complete remission (CR) was achieved in 5 patients, other 5 patients showed very good partial remission (VGPR), and in 4 patients partial remission (PR) was registered. RESULTS. As reported by the control follow-up on Day +100 after auto-HSCT, all patients demonstrated further deepening of antitumor response. By this time, CR in 11 (79 %) patients and VGPR in 2 (14 %) patients were registered, whereas 1 (7 %) patient maintained PR. Renal response and HD independence were achieved in 8 (57 %) out of 14 patients enrolled in the trial. In the total group (n = 14), the 3-year event-free survival was 50 % and overall survival was 78 %. CONCLUSION. Dialysis-dependent renal failure in MM patients is no contraindication to auto-HSCT. The latter will improve chemotherapy outcomes and make it possible to achieve renal response and HD independence.
- Open Access
- 10 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 115-123
Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.
- 10 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 115-123
Open AccessEfficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.
- Open Access
- 9 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 52-72
Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
Classical Hodgkin’s lymphoma (cHL) is a lymphoproliferative disease characterized by the presence of Hodgkin anderezovsky–Reed–Sternberg cells and a tumor microenvironment. Currently, much attention is paid to the microenvironment in cLH. A detailed understanding of the interaction between the tumor and its microenvironment opens up prospects for the cHL diagnosis and treatment. Innovative immunotherapeutic agents such as nivolumab make it possible to control and activate the immune response. Despite the high efficiency of standard protocols in young patients, therapy intensification is associated with organ toxicity and the development of secondary malignant neoplasms. At the same time, in elderly patients, the results of generally accepted antitumor treatment protocols should be considered suboptimal. In the last decade, the treatment of refractory cHL has improved significantly due to the use of immune checkpoint inhibitors.Taking into account the above, the priority issue in modern clinical hematology is to improve cHL treatment strategies not only in elderly but also in young patients by maintaining a balance between high efficacy and low toxicity. Moreover, the inclusion of nivolumab in first-line therapy is not only pathogenetically justified and effective, but also safe. The article presents data from clinical observations of the successful nivolumab use in combination with chemotherapy in patients with newly diagnosed cHL.
- 9 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 52-72
Open AccessNivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
Classical Hodgkin’s lymphoma (cHL) is a lymphoproliferative disease characterized by the presence of Hodgkin anderezovsky–Reed–Sternberg cells and a tumor microenvironment. Currently, much attention is paid to the microenvironment in cLH. A detailed understanding of the interaction between the tumor and its microenvironment opens up prospects for the cHL diagnosis and treatment. Innovative immunotherapeutic agents such as nivolumab make it possible to control and activate the immune response. Despite the high efficiency of standard protocols in young patients, therapy intensification is associated with organ toxicity and the development of secondary malignant neoplasms. At the same time, in elderly patients, the results of generally accepted antitumor treatment protocols should be considered suboptimal. In the last decade, the treatment of refractory cHL has improved significantly due to the use of immune checkpoint inhibitors.Taking into account the above, the priority issue in modern clinical hematology is to improve cHL treatment strategies not only in elderly but also in young patients by maintaining a balance between high efficacy and low toxicity. Moreover, the inclusion of nivolumab in first-line therapy is not only pathogenetically justified and effective, but also safe. The article presents data from clinical observations of the successful nivolumab use in combination with chemotherapy in patients with newly diagnosed cHL.
- Open Access
- 3 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 14-22
Treatment of elderly patients with acute myeloid leukemia: personal experience
Background. Acute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic system. Most patients with newly diagnosed AML are 65 years of age or older. Treatment of this cohort of patients is difficult due to the comorbidity of elderly patients and the genetic characteristics of hemoblastosis, which prevents the achievement of significant progress in treatment, in contrast to younger patients with AML. As domestic and foreign studies have shown, age is an independent universal prognosis factor for AML. In the era of targeted drugs, successful treatment of AML is becoming possible.Aim. To assess overall survival in elderly patients with AML, tolerability and effectiveness of various treatment regimens in patients with AML ≥65 years.Materials and methods. This paper presents our own experience in the treatment of elderly patients with AML in the hematology departments of the City Clinical Hospital No. 52. The study included patients over 65 years of age with AML from April 2022 to September 2023. A total of 40 patients were analyzed. To determine the risk factors for death, univariate and multivariate regression analyzes were performed using the logistic regression method. Variables that showed statistical significance on univariate analysis were included in the multivariate analysis. An analysis of 12‑month overall survival was also carried out using the Kaplan–Meier method with the construction of survival curves and calculation of median survival. A comparative analysis of two groups of patients treated with the AZA + EN and LdaraC regimens was carried out.Results. 63 % (n = 25) are men, 37 % (n = 15) are women. The median age was 75 years; all patients had complicated premorbid background. 53 % (n = 21) of patients were in the age range from 65 to 69 years, 47 % (n = 19) were over 70. Antitumor treatment was received by 88 % (n = 35) of patients. The remaining 5 underwent: best accompanying (n = 2), cytoreductive (early death at this stage) (n = 3) therapy. Complete remission after two cycles of therapy was achieved in 46 % (n = 16) of patients, and in 29 % (n = 10) it was maintained at the time of analysis. Early relapse occurred in 14 % (n = 5). Early mortality was recorded in 9 % (n = 3). Death was reported in 40 % (n = 16) of patients. 20 % (n = 7) of patients were refractory to first-line therapy, of which 36 % (n = 5) were treated with low doses of cytarabine (LdaraC), the rest to a combination of azacitidine (AZA) with venetoclax (EN). The number of relapses among patients on AZA + EN and LdaraC therapy was comparable.Conclusion. AZA + EN is the first-line treatment of choice in older patients with AML. The possibility of conducting this course in an outpatient setting makes it most convenient for both hematologists and patients. An important aspect in the treatment of AML in elderly patients is improving and maintaining quality of life.
- 3 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 14-22
Open AccessTreatment of elderly patients with acute myeloid leukemia: personal experience
Background. Acute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic system. Most patients with newly diagnosed AML are 65 years of age or older. Treatment of this cohort of patients is difficult due to the comorbidity of elderly patients and the genetic characteristics of hemoblastosis, which prevents the achievement of significant progress in treatment, in contrast to younger patients with AML. As domestic and foreign studies have shown, age is an independent universal prognosis factor for AML. In the era of targeted drugs, successful treatment of AML is becoming possible.Aim. To assess overall survival in elderly patients with AML, tolerability and effectiveness of various treatment regimens in patients with AML ≥65 years.Materials and methods. This paper presents our own experience in the treatment of elderly patients with AML in the hematology departments of the City Clinical Hospital No. 52. The study included patients over 65 years of age with AML from April 2022 to September 2023. A total of 40 patients were analyzed. To determine the risk factors for death, univariate and multivariate regression analyzes were performed using the logistic regression method. Variables that showed statistical significance on univariate analysis were included in the multivariate analysis. An analysis of 12‑month overall survival was also carried out using the Kaplan–Meier method with the construction of survival curves and calculation of median survival. A comparative analysis of two groups of patients treated with the AZA + EN and LdaraC regimens was carried out.Results. 63 % (n = 25) are men, 37 % (n = 15) are women. The median age was 75 years; all patients had complicated premorbid background. 53 % (n = 21) of patients were in the age range from 65 to 69 years, 47 % (n = 19) were over 70. Antitumor treatment was received by 88 % (n = 35) of patients. The remaining 5 underwent: best accompanying (n = 2), cytoreductive (early death at this stage) (n = 3) therapy. Complete remission after two cycles of therapy was achieved in 46 % (n = 16) of patients, and in 29 % (n = 10) it was maintained at the time of analysis. Early relapse occurred in 14 % (n = 5). Early mortality was recorded in 9 % (n = 3). Death was reported in 40 % (n = 16) of patients. 20 % (n = 7) of patients were refractory to first-line therapy, of which 36 % (n = 5) were treated with low doses of cytarabine (LdaraC), the rest to a combination of azacitidine (AZA) with venetoclax (EN). The number of relapses among patients on AZA + EN and LdaraC therapy was comparable.Conclusion. AZA + EN is the first-line treatment of choice in older patients with AML. The possibility of conducting this course in an outpatient setting makes it most convenient for both hematologists and patients. An important aspect in the treatment of AML in elderly patients is improving and maintaining quality of life.
- Open Access
- 1 October 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (4) , 360-369
The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease
AIM. To analyze our own experience in the use of the VRd regimen in the induction therapy for patients with newly diagnosed multiple myeloma (MM) complicated by the end-stage renal disease (ESRD). MATERIALS & METHODS. This prospective cohort trial enrolled 15 newly diagnosed MM patients with ESRD (eGFR < 15 mL/min/1.73 m2) in the period from February to October 2019. Six original RVd induction cycles were planned: lenalidomide 25 mg per os on Days 1, 4, 8, 11, and 15 (administered after hemodialysis), bortezomib 1.3 mg/m2 subcutaneously on Days 1, 4, 8, and 11, as well as dexamethasone 20 mg per os or IV on Days 1, 2, 4, 5, 8, 9, 11, and 12. Blood sampling for pharmacokinetic analysis was performed in 5 (33 %) patients prior to therapy (end-point 0) as well as 4, 24, and 96 hours after the first lenalidomide dose during the 1st RVd cycle. RESULTS. The median age of patients was 67 years (range 55–74 years); there were 9 women and 6 men. All of them were hemodialysis-dependent. The median GFR was 6.3 (5.7; 12.5) mL/min/1.73 m2. In all patients, the serum β2-microglobuline concentration was > 5.5 mg/L (ISS III = 100 %). In 4 (26.7 %) out of 15 patients, renal response was achieved (group I), whereas 11 (73.3 %) patients showed no renal recovery and remained hemodialysis-dependent (group II). Overall (hematologic) response was 80 % (CR 26.7 %, VGPR 20 %, PR 33.3 %). With the median follow-up of 4.64 years, the 5-year overall survival (OS) in all 15 patients was 33.3 ± 12.2 %. In group I (n = 4), life expectancy of patients was 4.45+, 1.81, 4.93+, and 4,68+ years. Out of them, 3 patients are being further followed-up, one died. In group II (n = 11; 9 events), the median OS was 1.75 years. The median maximum serum lenalidomide concentration as reported 4 hours after the first dose of the drug administration was 470 (364; 496) ng/mL. After 24 hours, the lenalidomide concentration decreased 5.7-fold to 82 (54; 269) ng/mL. CONCLUSION. The proposed original VRd regimen ensures high rates of overall response (80 %) and deep remissions (³ VGPR 46.7 %). The originality of the VRd regimen consisted in intermittent administration of 25 mg lenalidomide on Days 1, 4, 8, 11, and 15 after hemodialysis reaching a cumulative dose of 125 mg per 21-day cycle. The maximum lenalidomide concentration (Cmax) did not exceed that in patients with normal renal function and gradually decreased by the next hemodialysis session and the next drug administration. The incidence and severity of adverse events did not exceed those resulting from similar regimens for treatment of hemodialysis-dependent MM patients with ESRD.
- 1 October 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (4) , 360-369
Open AccessThe Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease
AIM. To analyze our own experience in the use of the VRd regimen in the induction therapy for patients with newly diagnosed multiple myeloma (MM) complicated by the end-stage renal disease (ESRD). MATERIALS & METHODS. This prospective cohort trial enrolled 15 newly diagnosed MM patients with ESRD (eGFR < 15 mL/min/1.73 m2) in the period from February to October 2019. Six original RVd induction cycles were planned: lenalidomide 25 mg per os on Days 1, 4, 8, 11, and 15 (administered after hemodialysis), bortezomib 1.3 mg/m2 subcutaneously on Days 1, 4, 8, and 11, as well as dexamethasone 20 mg per os or IV on Days 1, 2, 4, 5, 8, 9, 11, and 12. Blood sampling for pharmacokinetic analysis was performed in 5 (33 %) patients prior to therapy (end-point 0) as well as 4, 24, and 96 hours after the first lenalidomide dose during the 1st RVd cycle. RESULTS. The median age of patients was 67 years (range 55–74 years); there were 9 women and 6 men. All of them were hemodialysis-dependent. The median GFR was 6.3 (5.7; 12.5) mL/min/1.73 m2. In all patients, the serum β2-microglobuline concentration was > 5.5 mg/L (ISS III = 100 %). In 4 (26.7 %) out of 15 patients, renal response was achieved (group I), whereas 11 (73.3 %) patients showed no renal recovery and remained hemodialysis-dependent (group II). Overall (hematologic) response was 80 % (CR 26.7 %, VGPR 20 %, PR 33.3 %). With the median follow-up of 4.64 years, the 5-year overall survival (OS) in all 15 patients was 33.3 ± 12.2 %. In group I (n = 4), life expectancy of patients was 4.45+, 1.81, 4.93+, and 4,68+ years. Out of them, 3 patients are being further followed-up, one died. In group II (n = 11; 9 events), the median OS was 1.75 years. The median maximum serum lenalidomide concentration as reported 4 hours after the first dose of the drug administration was 470 (364; 496) ng/mL. After 24 hours, the lenalidomide concentration decreased 5.7-fold to 82 (54; 269) ng/mL. CONCLUSION. The proposed original VRd regimen ensures high rates of overall response (80 %) and deep remissions (³ VGPR 46.7 %). The originality of the VRd regimen consisted in intermittent administration of 25 mg lenalidomide on Days 1, 4, 8, 11, and 15 after hemodialysis reaching a cumulative dose of 125 mg per 21-day cycle. The maximum lenalidomide concentration (Cmax) did not exceed that in patients with normal renal function and gradually decreased by the next hemodialysis session and the next drug administration. The incidence and severity of adverse events did not exceed those resulting from similar regimens for treatment of hemodialysis-dependent MM patients with ESRD.
- Open Access
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 206-214
COVID-19 in patients with acute lymphoblastic leukemia
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as well as antitumor treatment, predisposes to the development of a more severe infection, as well as long-term SARS-CoV-2 persistence even after complete regression of COVID-19 symptoms. Thus, although after the emergence of the SARS-CoV-2 Omicron variant, coronavirus infection began to occur predominantly in a mild form, COVID-19 in ALL patients remains an urgent problem.Aim. To assess hospital survival of patients with ALL and concomitant coronavirus infection, to identify predictors of death and to evaluate the impact of program antitumor therapy on the outcome in this cohort of patients.Materials and methods. A retrospective analysis of ALL patients hospitalized in City Clinical Hospital No. 52 with coronavirus infection from February 2020 to December 2022 was conducted. Diagnosis and treatment of patients were carried out in accordance with valid at the time of hospitalization temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Univariate and multivariate regression analyses were performed to identify predictors of mortality in patients with ALL and COVID-19. Survival analysis was performed using the Kaplan–Meier method. A p 0.05 was considered statistically significant.Results. The study included 60 patients with ALL and concomitant coronavirus infection (30 men and 30 women). The median age was 42 years. Extremely severe coronavirus infection was observed in 25 % of patients in 2020–2021 and in 5 % of patients in 2022. Forty five patients received chemotherapy a month before hospitalization for COVID-19, 23 patients – during hospitalization. In-hospital mortality was 25 % (11 patients in 2020, 4 patients in 2021). The cause of death in 9 (60 %) cases was severe coronavirus infection; 4 (27 %) patients died as a result of severe bacterial complications, 2 (13 %) – due to ALL progression. In multivariate regression analysis, the following predictors had a statistically significant impact on the outcome: ALL relapse, absence of seroconversion at the time of outcome (anti-SARS-CoV-2 IgG level at the time of outcome 50 U/mL). When analyzing the impact of chemotherapy administered a month before or during hospitalization due to coronavirus infection, statistically significant values were not obtained for any of the factors.Conclusion. Considering the obtained results and international recommendations for the treatment of ALL patients with COVID-19, the decision on antitumor treatment for ALL patients when SARS-CoV-2 RNA is detected by polymerase chain reaction in an oropharyngeal swab should be made individually depending on the patient’s age, clinical manifestations of coronavirus infection, ALL status and the antitumor therapy phase. In addition, given the reduced antiviral response in ALL patients, special attention should be paid to the prevention of SARS-CoV-2 infection, and in case of disease development, passive immunization methods (virus-neutralizing monoclonal antibodies) should be considered as antiviral therapy.
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 206-214
Open AccessCOVID-19 in patients with acute lymphoblastic leukemia
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as well as antitumor treatment, predisposes to the development of a more severe infection, as well as long-term SARS-CoV-2 persistence even after complete regression of COVID-19 symptoms. Thus, although after the emergence of the SARS-CoV-2 Omicron variant, coronavirus infection began to occur predominantly in a mild form, COVID-19 in ALL patients remains an urgent problem.Aim. To assess hospital survival of patients with ALL and concomitant coronavirus infection, to identify predictors of death and to evaluate the impact of program antitumor therapy on the outcome in this cohort of patients.Materials and methods. A retrospective analysis of ALL patients hospitalized in City Clinical Hospital No. 52 with coronavirus infection from February 2020 to December 2022 was conducted. Diagnosis and treatment of patients were carried out in accordance with valid at the time of hospitalization temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Univariate and multivariate regression analyses were performed to identify predictors of mortality in patients with ALL and COVID-19. Survival analysis was performed using the Kaplan–Meier method. A p 0.05 was considered statistically significant.Results. The study included 60 patients with ALL and concomitant coronavirus infection (30 men and 30 women). The median age was 42 years. Extremely severe coronavirus infection was observed in 25 % of patients in 2020–2021 and in 5 % of patients in 2022. Forty five patients received chemotherapy a month before hospitalization for COVID-19, 23 patients – during hospitalization. In-hospital mortality was 25 % (11 patients in 2020, 4 patients in 2021). The cause of death in 9 (60 %) cases was severe coronavirus infection; 4 (27 %) patients died as a result of severe bacterial complications, 2 (13 %) – due to ALL progression. In multivariate regression analysis, the following predictors had a statistically significant impact on the outcome: ALL relapse, absence of seroconversion at the time of outcome (anti-SARS-CoV-2 IgG level at the time of outcome 50 U/mL). When analyzing the impact of chemotherapy administered a month before or during hospitalization due to coronavirus infection, statistically significant values were not obtained for any of the factors.Conclusion. Considering the obtained results and international recommendations for the treatment of ALL patients with COVID-19, the decision on antitumor treatment for ALL patients when SARS-CoV-2 RNA is detected by polymerase chain reaction in an oropharyngeal swab should be made individually depending on the patient’s age, clinical manifestations of coronavirus infection, ALL status and the antitumor therapy phase. In addition, given the reduced antiviral response in ALL patients, special attention should be paid to the prevention of SARS-CoV-2 infection, and in case of disease development, passive immunization methods (virus-neutralizing monoclonal antibodies) should be considered as antiviral therapy.
- Open Access
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 99-111
Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on Moscow permanent residents who were primary diagnosed with AML from January 2019 to November 2023. The effectiveness of antitumor therapy was assessed by the complete remissions rate, relapses, deaths, and 3-year overall and relapse-free survival. Data analysis performed as of 01.12.2023.Results. According to the Moscow Cancer Registry, from 01.01.2019 to 01.12.2023, the diagnosis of AML (except for acute promyelocytic leukemia) was established in 752 patients with a median age at the time of diagnosis of 64 (19– 94) years. In the studied sample, females slightly predominated: women – 56.6 % (n = 426), men – 43.4 % (n = 326). Of all patients included in the study, 36 % (n = 275) received intensive chemotherapy, while 57 % (n = 427) received low-intensity chemotherapy, and the remaining 7 % (n = 50) patients received best supportive care. Early mortality (first 60 days) in the total group was 16 % (n = 123), 20 % (n = 149) of patients were refractory to the therapy. Complete remission was achieved by 63 % (n = 473) of patients: 82 % (n = 225) of them received intensive chemotherapy, 58 % (n = 248) – low-intensity chemotherapy. Relapses occurred in 41 % (n = 194) of 473 patients who achieved complete remission. In the first remission, allogeneic hematopoietic stem cell transplantation was performed in 11 % (n = 79) of patients. With a median follow-up of 30.1 months, the 3-year overall survival in total group was 27 % (95 % confidence interval 23–32), and the 3-year relapse-free survival was 44 % (95 % confidence interval 37–51).Conclusion. The main problem in the treatment of adult AML patients remains high induction mortality and limited opportunities for allogeneic hematopoietic stem cell transplantation in real clinical practice, which emphasizes the need to develop transplant centers in Moscow.
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 99-111
Open AccessTreatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on Moscow permanent residents who were primary diagnosed with AML from January 2019 to November 2023. The effectiveness of antitumor therapy was assessed by the complete remissions rate, relapses, deaths, and 3-year overall and relapse-free survival. Data analysis performed as of 01.12.2023.Results. According to the Moscow Cancer Registry, from 01.01.2019 to 01.12.2023, the diagnosis of AML (except for acute promyelocytic leukemia) was established in 752 patients with a median age at the time of diagnosis of 64 (19– 94) years. In the studied sample, females slightly predominated: women – 56.6 % (n = 426), men – 43.4 % (n = 326). Of all patients included in the study, 36 % (n = 275) received intensive chemotherapy, while 57 % (n = 427) received low-intensity chemotherapy, and the remaining 7 % (n = 50) patients received best supportive care. Early mortality (first 60 days) in the total group was 16 % (n = 123), 20 % (n = 149) of patients were refractory to the therapy. Complete remission was achieved by 63 % (n = 473) of patients: 82 % (n = 225) of them received intensive chemotherapy, 58 % (n = 248) – low-intensity chemotherapy. Relapses occurred in 41 % (n = 194) of 473 patients who achieved complete remission. In the first remission, allogeneic hematopoietic stem cell transplantation was performed in 11 % (n = 79) of patients. With a median follow-up of 30.1 months, the 3-year overall survival in total group was 27 % (95 % confidence interval 23–32), and the 3-year relapse-free survival was 44 % (95 % confidence interval 37–51).Conclusion. The main problem in the treatment of adult AML patients remains high induction mortality and limited opportunities for allogeneic hematopoietic stem cell transplantation in real clinical practice, which emphasizes the need to develop transplant centers in Moscow.
- Open Access
- 2 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 101-108
Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.
- 2 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 101-108
Open AccessPersistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.